AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).

This shows all IPOs of last one year which got listed on both stock exchanges with its offer details, listing data and % change on price comparing offer price and annual returns. Click on company name ...